- In April 2025, A new Phase 1 clinical trial has opened for enrollment at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, for patients with high-grade neuroendocrine tumors. This trial will test a novel combination of immunotherapy drugs (nivolumab and ipilimumab) paired with an oncolytic (tumor-busting) virus, SVV-001 (Seneca Valley Virus-001), injected directly into the tumors
- In February 2025, The U.S. Food and Drug Administration (FDA) approved mirdametinib (Gomekli) for the treatment of neurofibromatosis type 1 (NF1) in patients who have symptomatic plexiform neurofibromas not amenable to complete surgical resection. While not directly a neuroendocrine tumor, NF1 is a genetic disorder that can cause various tumors, including some with neuroendocrine features. This approval provides a significant non-surgical option for a challenging tumor type within a related patient population
- In April 2024, Novartis received U.S. Food and Drug Administration (FDA) approval for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients. This approval marks a significant advancement, as Lutathera becomes the first radioligand therapy specifically approved for children with GEP-NETs, offering new hope for young patients and expanding the scope of precision medicine in pediatric oncology
- In March 2024, Crinetics Pharmaceuticals reported positive topline results from its Phase 2 open-label study of paltusotine, an investigational oral somatostatin receptor type 2 (SST2) nonpeptide agonist, in carcinoid syndrome. Paltusotine was shown to result in rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements associated with neuroendocrine tumors
- In December 2023, Bristol Myers Squibb (BMS) announced the acquisition of RayzeBio for approximately USD 4.1 billion. RayzeBio is a clinical-stage radiopharmaceutical company with a lead asset, RYZ101, targeting somatostatin receptor 2 (SSTR2), which is over-expressed in GEP-NETs and extensive stage small cell lung cancer (ES-SCLC). This acquisition significantly expands BMS's presence in the radiopharmaceutical therapeutics (RPTs) space and aims to strengthen its oncology pipeline
Frequently Asked Questions
The market is segmented based on Segmentation, By Classification (Functional NET and Non-Functional NET), Site (Lung, Pancreas, Gastrointestinal Tract (GI), and Appendicular), Grade (Grade 1, Grade 2, and Grade 3), Type (Diagnosis and Treatment), Product (Somatostatin Analogs, Targeted Therapy, and Chemotherapy), End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other) - Industry Trends and Forecast to 2032
.
The Global Neuroendocrine Tumors Market size was valued at USD 3.56 USD Billion in 2024.
The Global Neuroendocrine Tumors Market is projected to grow at a CAGR of 1.04% during the forecast period of 2025 to 2032.
The major players operating in the market include F. Hoffmann-La Roche Ltd , Bristol Myers Squibb , Viatris Inc. , Thermo Fisher Scientific Inc. , Novartis AG , Regeneron PharmaceuticalsInc. , Sun Pharmaceutical Industries Ltd. , Teva Pharmaceutical Industries Ltd. , Eli Lilly and Company , Lupin , Exact Sciences Corporation , Pfizer Inc. , Ipsen Pharma , Advanced Accelerator Applications , BioSynthema Inc. , Bionano GenomicsInc.U.S.), IlluminaInc. , GSK plc , HUTCHMED .
The market report covers data from the North America.
